Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Targene Biotech

Explore full profile

Molecular biology technology for early cancer diagnosis

Shamirpet mandal, India
Valuation $50–100M Last recorded · 2020
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Targene Biotech and the history behind them.

About Targene Biotech

Founded in 2009 and headquartered in Guangzhou, China, Targene Biotech is a developer of molecular biology technology focused on cancer diagnosis. The company provides cancer screening and early diagnostic kits to medical institutions, aiming to improve their operational efficiency.

Targene Biotech's core technologies include liquid biopsy and gene methylation. The firm's main market is Mainland China. It has successfully raised $14.3 million in funding from investors such as Guangzhou Ambition (LBP) Pharmaceutical Technology, Guangzhou Financial Innovation Investment, Guangzhou Fund, BGI Co-Win, and Funway Capital. The company is led by CEO Wen-Xue Tong.

Source: Dealroom company data

At a glance

Status
Operational
Headquarters
Shamirpet mandal, India
Open positions
None listed
Dealroom signal
22.6/100
Links
Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
OtherOther financing May 2022 $0 — Guangzhou Anbiping Pharmaceutical Technology ↗
SERIES A✓Equity / VC Mar 2020 $14M $56M BGI Co-Win ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Targene Biotech website traffic

Latest recorded traffic for Targene Biotech is 280 monthly website visits.

Latest monthly visits280
Monthly website visitsMar 2020–Oct 2022
Explore monthly traffic historyTrack growth over time and compare with peersBook a demo
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

0 profiles shownExplore the complete relationship graph →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • BGI Co-Win

Other known investors1 additional known investor

  • Guangzhou Anbiping Pharmaceutical Technology

Talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇮🇳 India · Shamirpet mandal HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Targene Biotech on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Targene Biotech’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.